Program
apraglutide
Also written as “Apraglutide”, “FE203799 GLP-2 analogue” and “FE 203799”.
Its studies are mostly in Short Bowel Syndrome · Graft vs Host Disease · Renal Insufficiency, Chronic · Hodgkin Disease, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Ironwood Pharmaceuticals | 92 open or running | phase 3since Oct 22, 2020 | Oct 22, 2020 | Oct 30, 2027phase 3 · NCT05018286 |
| GlyPharma Therapeutics | 30 open or running | phase 2since Nov 13, 2017 | Nov 13, 2017 | none ahead |
Also a collaborator on its studies: psi-cro.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 13, 2017First studies: 3 phase 2 studiesNew to GlyPharma TherapeuticsGlyPharma Therapeutics · NCT03417765, NCT03415594, NCT03408132
- Oct 22, 2020Ironwood Pharmaceuticals's first study: phase 3 study in Short Bowel SyndromeNew to Ironwood PharmaceuticalsIronwood Pharmaceuticals · NCT04627025 · 164 enrolled · United States, Argentina, Belgium and more
- Dec 30, 2020Phase 1 study in Renal Insufficiency, ChronicIronwood Pharmaceuticals · NCT04699032 · 16 enrolled · United States
- May 27, 2021Phase 2 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT04964986 · 10 enrolled · Belgium, France
- Jul 6, 2021Phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT05018286 · 158 enrolled · United States, Argentina, Belgium and more
- Feb 8, 2022Phase 2 study in Graft vs Host DiseaseIronwood Pharmaceuticals · NCT05415410 · 31 enrolled · United States, Germany, Portugal and more
- Jan 20, 2023Phase 1 study in Hepatic ImpairmentIronwood Pharmaceuticals · NCT05706623 · 16 enrolled · Germany, Slovakia
- Feb 22, 2023Phase 1 study in Healthy SubjectsIronwood Pharmaceuticals · NCT05995704 · 42 enrolled · Netherlands
- Jul 11, 2023Phase 1 study in Healthy SubjectsIronwood Pharmaceuticals · NCT06002555 · 34 enrolled · Netherlands
- Jul 12, 2026Phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT07742735 · 124 planned · United States, Argentina, Australia and more
Ahead
- Oct 30, 2027Primary completion: phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT05018286
- Oct 2028Primary completion: phase 3 study in Short Bowel SyndromeIronwood Pharmaceuticals · NCT07742735
TargetBeta
“A synthetic, long-acting glucagon-like peptide-2 (GLP-2) agonist, with intestinotrophic activity”NCIt, by rule
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07742735Short Bowel Syndrome · United States, Argentina, Australia and more | 3 | Recruiting | Ironwood Pharmaceuticals | Oct 2028 | 124 |
| NCT06002555Healthy Subjects · Netherlands | 1 | Completed | Ironwood Pharmaceuticals | Sep 22, 2023 | 34 |
| NCT05995704Healthy Subjects · Netherlands | 1 | Completed | Ironwood Pharmaceuticals | Jul 24, 2023 | 42 |
| NCT05706623Hepatic Impairment · Germany, Slovakia | 1 | Completed | Ironwood Pharmaceuticals | Apr 4, 2023 | 16 |
| NCT05415410Graft vs Host Disease · United States, Germany, Portugal and more | 2 | Terminated | Ironwood Pharmaceuticals | Dec 17, 2024 | 31 |
| NCT05018286Short Bowel Syndrome · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Ironwood Pharmaceuticals | Oct 30, 2027 | 158 |
| NCT04964986Short Bowel Syndrome · Belgium, France | 2 | Completed | Ironwood Pharmaceuticals | Jun 6, 2023 | 10 |
| NCT04699032Renal Insufficiency, Chronic · United States | 1 | Completed | Ironwood Pharmaceuticals | Jul 5, 2021 | 16 |
| NCT04627025Short Bowel Syndrome · United States, Argentina, Belgium and more | 3 | Completed | Ironwood Pharmaceuticals | Jan 2, 2024 | 164 |
| NCT03408132Short Bowel Syndrome · Denmark | 2 | Completed | GlyPharma Therapeutics | Oct 28, 2019 | 8 |
| NCT03415594Short Bowel Syndrome · Denmark | 2 | Completed | GlyPharma Therapeutics | Nov 21, 2019 | 8 |
| NCT03417765Lymphoma | 2 | Withdrawn | GlyPharma Therapeutics | Mar 31, 2019 | 0 |
How it is read
Names in the registry
- “Apraglutide”, 8 entries
- “FE203799 GLP-2 analogue”, 2 entries
- “apraglutide”, 1 entry
- “FE 203799”, 1 entry
- “FE203799”, 1 entry
Conditions, from the studies’ own filings
- Short Bowel Syndrome, 6 studies
- Graft vs Host Disease, 1 study
- Renal Insufficiency, Chronic, 1 study
- Hodgkin Disease, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.